Donor selection for adoptive immunotherapy with NK cells in AML patients: Comparison between analysis of lytic NK cell clones and phenotypical identification of alloreactive NK cell repertoire

被引:4
|
作者
Meazza, Raffaella [1 ]
Ruggeri, Loredana [2 ]
Guolo, Fabio [3 ,4 ]
Minetto, Paola [4 ]
Canevali, Paolo [1 ]
Loiacono, Fabrizio [1 ]
Ciardelli, Sara [2 ]
Bo, Alessandra [5 ]
Luchetti, Silvia [5 ]
Serio, Alberto [5 ]
Zannoni, Letizia [6 ]
Retiere, Christelle [7 ]
Colomar-Carando, Natalia [1 ]
Parisi, Sarah [8 ]
Curti, Antonio [8 ]
Lemoli, Roberto M. M. [3 ,4 ]
Pende, Daniela [1 ]
机构
[1] IRCCS Osped Policlin San Martino, Unita Operativa UO Immunol, Genoa, Italy
[2] Univ Perugia, Osped St Maria Misericordia, Dipartimento Med, Div Ematol & Immunol Clin, Perugia, Italy
[3] Univ Genoa, Dipartimento Med Interna DiMI, Clin Ematol, Genoa, Italy
[4] IRCCS Osped Policlin San Martino, Dipartimento Ematol & Oncol, Genoa, Italy
[5] IRCCS Osped Policlin San Martino, Lab Ctr Cellule Staminali & Terapie Cellulari, Genoa, Italy
[6] Univ Bologna, Dipartimento Med Specialist Diagnost & Sperimental, Bologna, Italy
[7] Univ Nantes, Inst Natl St & Rech Medicale INSERM, Ctr Natl Rech Sci CNRS, Ctr Rech Cance rol & Immunol Integree Nantes Anger, Nantes, France
[8] Univ Bologna, Ist Ematol Seragnoli, IRCCS Azienda Ospedaliero, Bologna, Italy
来源
FRONTIERS IN IMMUNOLOGY | 2023年 / 14卷
基金
欧盟地平线“2020”;
关键词
natural killer cells (NK cells); donor selection; NK alloreactivity; killer immunoglobulin-like receptors (KIR); human leucocyte antigen (HLA); adoptive immunotherapy; acute myeloid leukemia (AML); ACUTE MYELOID-LEUKEMIA; CLASS-I MOLECULES; NATURAL-KILLER-CELLS; INHIBITORY RECEPTOR; MHC MOLECULES; MISSING SELF; KIR; KIR3DL1; DIVERSITY; ALLELES;
D O I
10.3389/fimmu.2023.1111419
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Natural killer (NK) cell-based adoptive immunotherapy in leukemia patients is an emerging field of interest based on clinical evidence of efficacy and safety. Elderly acute myeloid leukemia (AML) patients have been successfully treated with NK cells from HLA-haploidentical donors, especially when high amounts of alloreactive NK cells were infused. The aim of this study was comparing two approaches to define the size of alloreactive NK cells in haploidentical donors for AML patients recruited in two clinical trials with the acronym "NK-AML" (NCT03955848), and "MRD-NK". The standard methodology was based on the frequency of NK cell clones capable of lysing the related patient-derived cells. The alternative approach consisted of the phenotypic identification of freshly derived NK cells expressing, as inhibitory receptors, only the inhibitory KIR(s) specific for the mismatched KIR-Ligand(s) (HLA-C1, HLA-C2, HLA-Bw4). However, in KIR2DS2(+) donors and HLA-C1(+) patients, the unavailability of reagents staining only the inhibitory counterpart (KIR2DL2/L3) may lead to an underestimated identification of the alloreactive NK cell subset. Conversely, in the case of HLA-C1 mismatch, the alloreactive NK cell subset could be overestimated due to the ability of KIR2DL2/L3 to recognize with low-affinity also HLA-C2. Especially in this context, the additional exclusion of LIR1-expressing cells might be relevant to refine the size of the alloreactive NK cell subset. We could also associate degranulation assays, using as effector cells IL-2 activated donor peripheral blood mononuclear cells (PBMC) or NK cells upon co-culture with the related patient target cells. The donor alloreactive NK cell subset always displayed the highest functional activity, confirming its identification accuracy by flow cytometry. Despite the phenotypic limitations and considering the proposed corrective actions, a good correlation was shown by the comparison of the two investigated approaches. In addition, the characterization of receptor expression on a fraction of NK cell clones revealed expected but also few unexpected patterns. Thus, in most instances, the quantification of phenotypically defined alloreactive NK cells from PBMC can provide data similar to the analysis of lytic clones, with several advantages, such as a shorter time to achieve the results and, perhaps, higher reproducibility/feasibility in many laboratories.
引用
收藏
页数:14
相关论文
共 26 条
  • [1] Larger Size of Donor Alloreactive NK Cell Repertoire Correlates with Better Response to NK Cell Immunotherapy in Elderly Acute Myeloid Leukemia Patients
    Curti, Antonio
    Ruggeri, Loredana
    Parisi, Sarah
    Bontadini, Andrea
    Dan, Elisa
    Motta, Maria Rosa
    Rizzi, Simonetta
    Trabanelli, Sara
    Ocadlikova, Darina
    Lecciso, Mariangela
    Giudice, Valeria
    Fruet, Fiorenza
    Urbani, Elena
    Papayannidis, Cristina
    Martinelli, Giovanni
    Bandini, Giuseppe
    Bonifazi, Francesca
    Lewis, Russell E.
    Cavo, Michele
    Velardi, Andrea
    Lemoli, Roberto M.
    CLINICAL CANCER RESEARCH, 2016, 22 (08) : 1914 - 1921
  • [2] Long-Term Outcome After Adoptive Immunotherapy With Natural Killer Cells: Alloreactive NK Cell Dose Still Matters
    Parisi, Sarah
    Ruggeri, Loredana
    Dan, Elisa
    Rizzi, Simonetta
    Sinigaglia, Barbara
    Ocadlikova, Darina
    Bontadini, Andrea
    Giudice, Valeria
    Urbani, Elena
    Ciardelli, Sara
    Sartor, Chiara
    Cristiano, Gianluca
    Nanni, Jacopo
    Zannoni, Letizia
    Chirumbolo, Gabriella
    Arpinati, Mario
    Lewis, Russell E.
    Bonifazi, Francesca
    Marconi, Giovanni
    Martinelli, Giovanni
    Papayannidis, Cristina
    Paolini, Stefania
    Velardi, Andrea
    Cavo, Michele
    Lemoli, Roberto M.
    Curti, Antonio
    FRONTIERS IN IMMUNOLOGY, 2022, 12
  • [3] The Advantages and Challenges of Anticancer Dendritic Cell Vaccines and NK Cells in Adoptive Cell Immunotherapy
    Abakushina, Elena V.
    Popova, Liubov I.
    Zamyatnin, Andrey A., Jr.
    Werner, Jens
    Mikhailovsky, Nikolay V.
    Bazhin, Alexandr V.
    VACCINES, 2021, 9 (11)
  • [4] Selection and expansion of natural killer cells for NK cell-based immunotherapy
    Becker, Petra S. A.
    Suck, Garnet
    Nowakowska, Paulina
    Ullrich, Evelyn
    Seifried, Erhard
    Bader, Peter
    Tonn, Torsten
    Seidl, Christian
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2016, 65 (04) : 477 - 484
  • [5] Cryopreservation of NK and T Cells Without DMSO for Adoptive Cell-Based Immunotherapy
    Yao, Xue
    Matosevic, Sandro
    BIODRUGS, 2021, 35 (05) : 529 - 545
  • [6] Beyond αβ T cells: NK, iNKT, and γδT cell biology in leukemic patients and potential for off-the-shelf adoptive cell therapies for AML
    Kent, Andrew
    Crump, Lyndsey S.
    Davila, Eduardo
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [7] Selection and expansion of natural killer cells for NK cell-based immunotherapy
    Petra S. A. Becker
    Garnet Suck
    Paulina Nowakowska
    Evelyn Ullrich
    Erhard Seifried
    Peter Bader
    Torsten Tonn
    Christian Seidl
    Cancer Immunology, Immunotherapy, 2016, 65 : 477 - 484
  • [8] NK Cell Transcripts and NK Cells in Kidney Biopsies from Patients with Donor-Specific Antibodies: Evidence for NK Cell Involvement in Antibody-Mediated Rejection
    Hidalgo, L. G.
    Sis, B.
    Sellares, J.
    Campbell, P. M.
    Mengel, M.
    Einecke, G.
    Chang, J.
    Halloran, P. F.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2010, 10 (08) : 1812 - 1822
  • [9] Human NK cells in acute myeloid leukaemia patients: analysis of NK cell-activating receptors and their ligands
    Sanchez-Correa, Beatriz
    Morgado, Sara
    Gayoso, Inmaculada
    Bergua, Juan M.
    Casado, Javier G.
    Jose Arcos, Maria
    Luisa Bengochea, Maria
    Duran, Esther
    Solana, Rafael
    Tarazona, Raquel
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2011, 60 (08) : 1195 - 1205
  • [10] NK cell expression of natural cytotoxicity receptors may determine relapse risk in older AML patients undergoing immunotherapy for remission maintenance
    Martner, Anna
    Rydstrom, Anna
    Riise, Rebecca E.
    Aurelius, Johan
    Brune, Mats
    Foa, Robin
    Hellstrand, Kristoffer
    Thoren, Fredrik B.
    ONCOTARGET, 2015, 6 (40) : 42569 - 42574